Literature DB >> 20653674

A haplotype of CYP2C9 associated with warfarin sensitivity in mechanical heart valve replacement patients.

Su-Jun Lee1, Yin Jin Jang, Eun-Young Cha, Ho-Sook Kim, Sang Seop Lee, Jae-Gook Shin.   

Abstract

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT * CYP2C9 single nucleotide polymorphisms (SNPs) are important in safe and effective oral anticoagulation with warfarin use. * Although CYP2C9*2 and *3 are important genetic factors for the warfarin dose, one of the CYP2C9 SNPs, IVS-65G>C, has been suggested to be associated with warfarin sensitivity. However, as of yet, there has been no explanation about the possible mechanism and linkage analysis. WHAT THIS PAPER ADDS * New information on CYP2C9 SNPs and their occurrences in common haplotype structures in healthy unrelated Koreans and in individuals who require low warfarin dose after mechanical heart valve replacements (MHVRs) were studied. * Additional evidence showed that an Asian dominant haplotype consisting of -1565C>T, -1188T>C, IVS3+197G>A, IVS3-334C>T, IVS3-65G>C, IVS4-115A>G and IVS5-73A>G could be associated with a low warfarin maintenance dose in mechanical heart valve replacement (MHVR) patients. AIMS The objectives of this study were to determine the distribution of CYP2C9 variants in Koreans and investigate their association with warfarin dose requirements in patients who received MHVRs. METHODS All nine exons, intron-exon junction, and promoter region of CYP2C9 were amplified and directly sequenced in 50 healthy normal Koreans. Additional direct DNA sequencing of the CYP2C9 gene was conducted in 36 of the 267 MHVR patients who required low maintenance warfarin doses without carrying CYP2C9*3 and VKORC1 1173T mutations. The effects of CYP2C9 genetics on warfarin maintenance dose were assessed in 267 MHVR patients. RESULTS Thirty-nine single nucleotide polymorphisms (SNPs) including seven previously unidentified SNPs were identified in 50 Koreans by direct DNA sequencing. One of the CYP2C9 haplotypes exhibited an association with warfarin low dose requirement. The adjusted odds ratio for the haplotype between the low dose group and the normal subjects was 2.5 (95% confidence interval 1.05, 6.16). This haplotype consisting of -1565C>T, -1188T>C, IVS3+197G>A, IVS3-334C>T, IVS3-65G>C, IVS4-115A>G, and IVS5-73A>G was found in 15% of 36 MHVR patients who required low warfarin doses, while 4% of 50 normal healthy subjects exhibited this haplotype. One of the SNPs comprising this haplotype, -1565C>T, apparently changed a protein binding pattern as observed in electrophoretic mobility shift assay. CONCLUSION The haplotype including -1565C>T, -1188T>C, IVS3+197G>A, IVS3-334C>T, IVS3-65G>C, IVS4-115A>G, and IVS5-73A>G seems to be associated with low warfarin dose requirement and this haplotype could be considered in the development of a warfarin dose prediction model for Asian populations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20653674      PMCID: PMC2911551          DOI: 10.1111/j.1365-2125.2010.03688.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  32 in total

1.  The structure of haplotype blocks in the human genome.

Authors:  Stacey B Gabriel; Stephen F Schaffner; Huy Nguyen; Jamie M Moore; Jessica Roy; Brendan Blumenstiel; John Higgins; Matthew DeFelice; Amy Lochner; Maura Faggart; Shau Neen Liu-Cordero; Charles Rotimi; Adebowale Adeyemo; Richard Cooper; Ryk Ward; Eric S Lander; Mark J Daly; David Altshuler
Journal:  Science       Date:  2002-05-23       Impact factor: 47.728

2.  Discovery of new potentially defective alleles of human CYP2C9.

Authors:  Joyce Blaisdell; Lucia F Jorge-Nebert; Sherry Coulter; Stephen S Ferguson; Su-Jun Lee; Brian Chanas; Tina Xi; Harvey Mohrenweiser; Burhan Ghanayem; Joyce A Goldstein
Journal:  Pharmacogenetics       Date:  2004-08

Review 3.  Summary of information on human CYP enzymes: human P450 metabolism data.

Authors:  Slobodan Rendic
Journal:  Drug Metab Rev       Date:  2002 Feb-May       Impact factor: 4.518

4.  Genetic polymorphisms and functional characterization of the 5'-flanking region of the human CYP2C9 gene: in vitro and in vivo studies.

Authors:  M Shintani; I Ieiri; K Inoue; K Mamiya; H Ninomiya; N Tashiro; S Higuchi; K Otsubo
Journal:  Clin Pharmacol Ther       Date:  2001-08       Impact factor: 6.875

5.  Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism.

Authors:  Barry P King; Tayyaba I Khan; Guruprasad P Aithal; Farhad Kamali; Ann K Daly
Journal:  Pharmacogenetics       Date:  2004-12

6.  Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.

Authors:  Mitchell K Higashi; David L Veenstra; L Midori Kondo; Ann K Wittkowsky; Sengkeo L Srinouanprachanh; Fred M Farin; Allan E Rettie
Journal:  JAMA       Date:  2002-04-03       Impact factor: 56.272

7.  Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population.

Authors:  M G Scordo; E Aklillu; U Yasar; M L Dahl; E Spina; M Ingelman-Sundberg
Journal:  Br J Clin Pharmacol       Date:  2001-10       Impact factor: 4.335

8.  Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation : a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group.

Authors:  T Yamaguchi
Journal:  Stroke       Date:  2000-04       Impact factor: 7.914

9.  Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients.

Authors:  A Y Leung; H C Chow; Y L Kwong; A K Lie; A T Fung; W H Chow; A S Yip; R Liang
Journal:  Blood       Date:  2001-10-15       Impact factor: 22.113

10.  Functional impact of CYP2C95, CYP2C96, CYP2C98, and CYP2C911 in vivo among black Africans.

Authors:  Aurel C Allabi; Jean-Luc Gala; Yves Horsmans; Melih Onder Babaoglu; Atila Bozkurt; Michel Heusterspreute; Umit Yasar
Journal:  Clin Pharmacol Ther       Date:  2004-08       Impact factor: 6.875

View more
  3 in total

1.  Editors' pick 2010.

Authors:  Yoon K Loke; Albert Ferro; Lionel D Lewis; Adam F Cohen; Andrew Somogyi; James M Ritter
Journal:  Br J Clin Pharmacol       Date:  2011-01       Impact factor: 4.335

2.  CYP2C9 promoter variable number tandem repeat polymorphism regulates mRNA expression in human livers.

Authors:  Danxin Wang; Xiaochun Sun; Yan Gong; Brian E Gawronski; Taimour Y Langaee; Mohamed Hossam A Shahin; Sherief I Khalifa; Julie A Johnson
Journal:  Drug Metab Dispos       Date:  2012-01-30       Impact factor: 3.922

3.  Search for the molecular basis of ultra-rapid CYP2C9-catalysed metabolism: relationship between SNP IVS8-109A>T and the losartan metabolism phenotype in Swedes.

Authors:  Fazleen H M Hatta; Lay Kek Teh; Anders Helldén; Karin Engström Hellgren; Hyung-Keun Roh; Mohd Zaki Salleh; Eleni Aklillu; Leif Bertilsson
Journal:  Eur J Clin Pharmacol       Date:  2012-02-01       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.